Media
News and press releases
Welcome to our media section. Check out the latest news and press releases from Cinclus Pharma and don’t hesitate to contact us if you need more information.
Latest pressreleases
Latest News
Cinclus Pharma at Redeye Investor Forum 2024
Christer Ahlberg, CEO of Cinclus Pharma, was invited to present the company's latest updates and the development of linaprazan glurate at the Redeye Investor Forum in Gothenburg on April 18, 2024.
Cinclus Pharma presented at ABGSC investor days
Cinclus Pharma's CEO, Christer Ahlberg, presented Cinclus Pharma at the ABGCS seminar on November 22-23.
Cinclus Pharma announces positive FDA interaction
Cinclus Pharma today announces that the company has completed a successful so-called end-of-phase-II meeting, with the US Food and Drug Administration (FDA) for the indication erosive gastroesophageal reflux disease (eGERD). The FDA broadly accepted…
Cinclus Pharma's phase II eGERD study in two presentations at UEG
Two abstracts from Cinclus Pharma's phase II study, LEED, on its leading drug candidate linaprazan glurate, developed for the treatment of moderate to severe erosive GERD ("eGERD"), are being presented at the leading gastro conference United European…
Cinclus Pharma in media
New research advances for Linc-owned pharmaceutical company
2022-11-04[Swedish link] Cinclus Pharma har presenterat positiva resultat i en fas 2-studie kring en behandling av magsyrarelaterade besvär.
Cinclus Pharma raises a quarter of a billion SEK - EQT founder among investors
2022-05-20|Swedish link] Cinclus Pharma tar in nära en kvarts miljard kronor i en riktad emission inför bolagets stundande börsnotering. Riskkapitalfonden Eir...
Cinclus raises 240 million for Losec follow-up
2022-05-20[Swedish link] Cinclus Pharma tar in cirka 240 miljoner kronor i en nyemission. Målet: att ta fram en uppföljare till magsårsläkemedlen Losec och Nexium...
Telegram: Bengt Julanders Linc invests in Cinclus Pharma
2022-05-20[Swedish link] Forskningsbolaget Cinclus Pharma genomför en kapitalanskaffning där bolaget tar in cirka 240 miljoner ...
Telegram: Cinclus Pharma raises SEK 240 million
2022-05-20[Swedish link] Cinclus Pharma, ett biofarmaceutiskt företag, har rest cirka 240 miljoner kronor genom en riktad nyemission. Syftet är att anskaffa ...
